Homeland Nickel announced US Forest Service approval for its sonic drilling plan at the Red Flat Nickel Project, with environmental and cultural reviews underway. The company also completed data recompilation for Red Flat and Cleopatra projects, enabling updated resource estimates and accelerating economic assessments expected by Q4 2026. Homeland closed a $3.04 million private placement financing to fund exploration and corporate activities, with insiders participating under regulatory exemptions. These developments position Homeland to advance its nickel projects in Oregon, including the largest undeveloped nickel resource in the continental US at Cleopatra.
Homeland's exploration and corporate update is presented here with Pluang's Basic Materials sector data for context. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 17, 2026 20:12 WIB: Among 31 priced US stocks, 28 rose and 3 fell. Wheaton Precious Metals Corp (WPM) led with a price of USD 151.30 and a 3.11% gain, fully bought on Pluang with a typical hold time of 64 days. Barrick Gold Corp (B) traded at USD 43.80, up 2.94%, but saw 87% sell activity. Newmont Corporation (NEM) was priced at USD 125.30, up 2.91%, with 81% sell orders and a 57-day hold time.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
